Fig. 3.

MenSC transplantation improves ovarian function after chemotherapy-induced injury. a Schematic of the experimental procedure used to explore the reparative effects of MenSCs in POF mice. b Changes in body weight between three groups (data expressed as mean ± SEM, *P < 0.05). c Changes in ovary weight across the three groups after 7 and 21 days (data expressed as mean ± SEM, *P < 0.05). d Macroscopic ovarian ovarian sizes in the three groups after 21 days. e Representative images showing H & E-stained ovary tissue sections in each group after 7 and 21 days. Scale bars = 100 μm. f Changes in follicle numbers in the three groups at 7 days (a) and 21 days (b) after MenSC transplantation (data expressed as mean ± SEM, *P < 0.05). g Serum E2 levels measured in each of the three groups. h Serum FSH levels measured in each of the three groups (data expressed as mean ± SEM, *P < 0.05). i Representative photograph showing TUNEL staining in ovary tissue sections after 7 days in each of the three groups. j Photograph showing TUNEL staining in ovary tissue sections after 21 days in each of the three groups. TUNEL-positive cells labelled green, and nuclei labelled blue (DAPI). Scale bars = 200 μm. k Quantitative analysis showing the percentage of TUNEL-positive cells in each group at 7 and 21 days after treatment (data expressed as mean ± SEM, *P < 0.05). CDDP cisplatin, DAPI 4′,6-diamidino-2-phenylindole, E2 oestradiol, FSH follicle-stimulating hormone, H&E haematoxylin and eosin, MenSC menstrual-derived stem cell, PBS phosphate-buffered saline, POF premature ovarian failure, TUNEL terminal deoxynucleotidyl transferase mediated dUTP nick end labelling